343 related articles for article (PubMed ID: 3009181)
21. Secondary-site binding of Glu-plasmin, Lys-plasmin and miniplasmin to fibrin.
Suenson E; Thorsen S
Biochem J; 1981 Sep; 197(3):619-28. PubMed ID: 6459779
[TBL] [Abstract][Full Text] [Related]
22. Different molecular forms of plasminogen and plasmin produced by urokinase in human plasma and their relation to protease inhibitors and lysis of fibrinogen and fibrin.
Müllertz S
Biochem J; 1974 Nov; 143(2):273-83. PubMed ID: 4282470
[TBL] [Abstract][Full Text] [Related]
23. Human plasma alpha-cysteine proteinase inhibitor. Purification by affinity chromatography, characterization and isolation of an active fragment.
Gounaris AD; Brown MA; Barrett AJ
Biochem J; 1984 Jul; 221(2):445-52. PubMed ID: 6548132
[TBL] [Abstract][Full Text] [Related]
24. alpha 2-Antiplasmin Enschede: dysfunctional alpha 2-antiplasmin molecule associated with an autosomal recessive hemorrhagic disorder.
Kluft C; Nieuwenhuis HK; Rijken DC; Groeneveld E; Wijngaards G; van Berkel W; Dooijewaard G; Sixma JJ
J Clin Invest; 1987 Nov; 80(5):1391-400. PubMed ID: 2445779
[TBL] [Abstract][Full Text] [Related]
25. Plasminogen binding by alpha 2-antiplasmin and histidine-rich glycoprotein does not inhibit plasminogen activation at the surface of fibrin.
Angles-Cano E; Rouy D; Lijnen HR
Biochim Biophys Acta; 1992 Dec; 1156(1):34-42. PubMed ID: 1472536
[TBL] [Abstract][Full Text] [Related]
26. Purification of high and low molecular weight plasminogen activator inhibitor 1 from fibrosarcoma cell-line HT 1080 conditioned medium.
Lindahl T; Wiman B
Biochim Biophys Acta; 1989 Feb; 994(3):253-7. PubMed ID: 2493266
[TBL] [Abstract][Full Text] [Related]
27. Purification and characterization of mouse alpha-lactalbumin and preparation of its antibody.
Nagamatsu Y; Oka T
Biochem J; 1980 Jan; 185(1):227-37. PubMed ID: 6769429
[TBL] [Abstract][Full Text] [Related]
28. The heparin-binding site in tetranectin is located in the N-terminal region and binding does not involve the carbohydrate recognition domain.
Lorentsen RH; Graversen JH; Caterer NR; Thogersen HC; Etzerodt M
Biochem J; 2000 Apr; 347 Pt 1(Pt 1):83-7. PubMed ID: 10727405
[TBL] [Abstract][Full Text] [Related]
29. Large-scale purification of human tissue-type plasminogen activator using monoclonal antibodies.
Einarsson M; Brandt J; Kaplan L
Biochim Biophys Acta; 1985 Jul; 830(1):1-10. PubMed ID: 4040396
[TBL] [Abstract][Full Text] [Related]
30. Tetranectin-binding site on plasminogen kringle 4 involves the lysine-binding pocket and at least one additional amino acid residue.
Graversen JH; Sigurskjold BW; Thøgersen HC; Etzerodt M
Biochemistry; 2000 Jun; 39(25):7414-9. PubMed ID: 10858289
[TBL] [Abstract][Full Text] [Related]
31. Ca2+-binding protein from human kidney. Purification and properties.
Staun M; Norén O; Sjöström H
Biochem J; 1984 Jan; 217(1):229-37. PubMed ID: 6421283
[TBL] [Abstract][Full Text] [Related]
32. Purification and characterization of a plasminogen activator inhibitor 1 binding protein from human plasma. Identification as a multimeric form of S protein (vitronectin).
Declerck PJ; De Mol M; Alessi MC; Baudner S; Pâques EP; Preissner KT; Müller-Berghaus G; Collen D
J Biol Chem; 1988 Oct; 263(30):15454-61. PubMed ID: 2459123
[TBL] [Abstract][Full Text] [Related]
33. The effect of heparin on the affinity chromatography of plasminogen. Demonstration of heparin-plasminogen interaction.
Hatton MW; Regoeczi E
Biochim Biophys Acta; 1975 Apr; 386(2):451-60. PubMed ID: 1138880
[TBL] [Abstract][Full Text] [Related]
34. Purification and biological characterization of human hepatopoietin A, a polypeptide growth factor for hepatocytes.
Zarnegar R; Michalopoulos G
Cancer Res; 1989 Jun; 49(12):3314-20. PubMed ID: 2524251
[TBL] [Abstract][Full Text] [Related]
35. Binding and activation of plasminogen at the surface of Staphylococcus aureus. Increase in affinity after conversion to the Lys form of the ligand.
Kuusela P; Saksela O
Eur J Biochem; 1990 Nov; 193(3):759-65. PubMed ID: 1701146
[TBL] [Abstract][Full Text] [Related]
36. Mechanisms of activation of mammalian plasma fibrinolytic systems with streptokinase and with recombinant staphylokinase.
Collen D; Van Hoef B; Schlott B; Hartmann M; Gührs KH; Lijnen HR
Eur J Biochem; 1993 Aug; 216(1):307-14. PubMed ID: 7689966
[TBL] [Abstract][Full Text] [Related]
37. Expression, purification, and characterization of the recombinant kringle 1 domain from tissue-type plasminogen activator.
DeSerrano VS; Menhart N; Castellino FJ
Arch Biochem Biophys; 1992 Apr; 294(1):282-90. PubMed ID: 1550352
[TBL] [Abstract][Full Text] [Related]
38. Primary structure of tetranectin, a plasminogen kringle 4 binding plasma protein: homology with asialoglycoprotein receptors and cartilage proteoglycan core protein.
Fuhlendorff J; Clemmensen I; Magnusson S
Biochemistry; 1987 Oct; 26(21):6757-64. PubMed ID: 3427041
[TBL] [Abstract][Full Text] [Related]
39. Elements of the fibrinolytic system.
Lijnen HR
Ann N Y Acad Sci; 2001; 936():226-36. PubMed ID: 11460480
[TBL] [Abstract][Full Text] [Related]
40. Identification of an inhibitor of tissue-type plasminogen activator-mediated fibrinolysis in human neutrophils. A role for defensin.
Higazi AA; Barghouti II; Abu-Much R
J Biol Chem; 1995 Apr; 270(16):9472-7. PubMed ID: 7721874
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
